halofuginone has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Jonge, MJ; Dumez, H; Lacombe, D; Marréaud, S; Punt, CJ; Snyder, D; van Oosterom, A; Verweij, J; Yamaguchi, T; Yarkoni, S | 1 |
| Abramovitch, R; Dafni, H; Nagler, A; Neeman, M; Pines, M | 1 |
1 trial(s) available for halofuginone and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Fatigue; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Piperidines; Quinazolines; Quinazolinones; Vomiting | 2006 |
1 other study(ies) available for halofuginone and Neoplasms
| Article | Year |
|---|---|
Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Topics: Animals; Antineoplastic Agents; Collagen; Dose-Response Relationship, Drug; In Situ Hybridization; Kinetics; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Time Factors; Tumor Cells, Cultured; Wound Healing | 1999 |